Safety, Tolerability, and Pharmacokinetic Study of TRK-250 for Patients With Idiopathic Pulmonary Fibrosis

• Status: Recruiting
• Trial end date: 2022-04-01
• Target enrollment: 0
• Participant gender: All

Summary

TRK-250 is a nucleic acid medicine that inhibits the progression of pulmonary fibrosis by selectively suppressing the expression of transforming growth factor-beta 1 (TGF-β1) protein, at the gene expression level. This study is a double-blind, randomized, placebo-controlled Phase I study. The primary objective of the study is to assess the safety and tolerability of single and multiple inhaled doses of TRK-250 in subjects with idiopathic pulmonary fibrosis (IPF).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Toray Industries, Inc

Criteria

Inclusion Criteria:

• Clinical, radiographic, and histologic features consistent with the diagnosis of IPF

• SpO2 ≥90% at rest by pulse oximetry while breathing ambient air.

• FVC ≥50% of predicted.

• FEV1 ≥50% of predicted.

• Ratio of FEV1 to FVC ≥0.7.

• DLCO corrected for hemoglobin 30% to 79% of predicted, inclusive.

Exclusion Criteria:

• History of acute exacerbation of IPF or respiratory tract infection within 3 months prior to Screening.

• Planned surgery during the study.

• History of malignant tumor within 5 years prior to Screening.

• History of emphysema or clinically significant respiratory diseases (other than IPF).

• Other known causes of interstitial lung disease (eg, drug toxicities, environmental exposures, connective tissue diseases).

• End-stage fibrotic disease expected to require organ transplantation within 6 months.

• Taking a systemic corticosteroid, cytotoxic therapy, vasodilator therapy for pulmonary hypertension, or unapproved treatment for IPF within 4 weeks prior to Screening. (Treatment with pirfenidone or nintedanib, though not both concurrently, is permitted, provided that the subject has been on a stable dose for at least 4 weeks prior to Screening and it is anticipated the dose will remain unchanged throughout enrollment.)